These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32563354)

  • 41. [Dexamethasone-cyclophosphamide pulse therapy in bullous autoimmune dermatoses].
    Appelhans M; Bonsmann G; Orge C; Bröcker EB
    Hautarzt; 1993 Mar; 44(3):143-7. PubMed ID: 8463094
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
    Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
    Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of rituximab in the treatment of mucous membrane pemphigoid: An analytic review.
    Farooq MM; Miloslavsky EM; Konikov N; Ahmed AR
    Autoimmun Rev; 2022 Aug; 21(8):103119. PubMed ID: 35688385
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and management of chronic hepatitis B in pemphigus and pemphigoid patients: New evidence for the safety of rituximab.
    Aryanian Z; Tahooneban A; Balighi K; Daneshpazhooh M; Mahmoudi H; Soori T; Mohseniafshar Z; Tavakolpour S; Hatami P
    Dermatol Ther; 2022 Nov; 35(11):e15783. PubMed ID: 36001617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients.
    Lourari S; Herve C; Doffoel-Hantz V; Meyer N; Bulai-Livideanu C; Viraben R; Maza A; Adoue D; Bedane C; Paul C
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1238-40. PubMed ID: 21054575
    [No Abstract]   [Full Text] [Related]  

  • 46. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up.
    Ahmed AR; Shetty S; Kaveri S; Spigelman ZS
    J Am Acad Dermatol; 2016 Apr; 74(4):700-8.e3. PubMed ID: 26851830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of bullous pemphigoid and pemphigus. The French experience, 2009 update.
    Roujeau JC; Ingen-Housz-Oro S; Leroux C; Joly P
    G Ital Dermatol Venereol; 2009 Aug; 144(4):333-8. PubMed ID: 19755939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-Dose Rituximab for Bullous Pemphigoid. Protocol and Single-Center Experience.
    Suárez-Carantoña C; Jiménez-Cauhé J; González-García A; Fernández-Guarino M; Asunción Ballester M
    Actas Dermosifiliogr; 2023 Jan; 114(1):62-68. PubMed ID: 35868546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-Dose Rituximab for Bullous Pemphigoid. Protocol and Single-Center Experience.
    Suárez-Carantoña C; Jiménez-Cauhé J; González-García A; Fernández-Guarino M; Asunción Ballester M
    Actas Dermosifiliogr; 2023 Jan; 114(1):T62-T68. PubMed ID: 36368587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autoimmune diseases of the skin.
    Bystryn JC
    Allergy Proc; 1989; 10(6):393-6. PubMed ID: 2628160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Remission of Anti-laminin 332 Mucous Membrane Pemphigoid Associated with Non-small Cell Lung Cancer after Therapy with Rituximab and Intravenous Immunoglobulin.
    Tarnowietzki E; Peters T; Kraus L; Schmidt E; Scharffetter-Kochanek K
    Acta Derm Venereol; 2020 Oct; 100(17):adv00301. PubMed ID: 32852563
    [No Abstract]   [Full Text] [Related]  

  • 53. Bullous diseases: Kids are not just little people.
    Marathe K; Lu J; Morel KD
    Clin Dermatol; 2015; 33(6):644-56. PubMed ID: 26686016
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Autoimmune blistering diseases].
    Duvert-Lehembre S; Joly P
    Rev Med Interne; 2014 Mar; 35(3):166-73. PubMed ID: 23747156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concomitant pemphigus vulgaris and pemphigoid gestationis: a case report and review of the literature.
    Vin H; Seyfer SJ; McClain CM; Hsu S
    Dermatol Online J; 2016 Jan; 22(1):. PubMed ID: 26990471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature.
    Kremer N; Snast I; Cohen ES; Hodak E; Mimouni D; Lapidoth M; Mazor S; Levi A
    Am J Clin Dermatol; 2019 Apr; 20(2):209-216. PubMed ID: 30421306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of severe refractory pemphigus vulgaris with rituximab].
    Pitarch G; Sánchez-Carazo JL; Pardo J; Torrijos A; Roche E; Fortea JM
    Actas Dermosifiliogr; 2006; 97(1):48-51. PubMed ID: 16540052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ; Wolverton SE
    J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coexistence of psoriasis vulgaris and bullous diseases.
    Grunwald MH; David M; Feuerman EJ
    J Am Acad Dermatol; 1985 Aug; 13(2 Pt 1):224-8. PubMed ID: 3900156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The distribution of IgG subclasses in pemphigoid gestationis: PG factor is an IgG1 autoantibody.
    Kelly SE; Cerio R; Bhogal BS; Black MM
    J Invest Dermatol; 1989 May; 92(5):695-8. PubMed ID: 2654296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.